Document resource
Intrahepatic cholangiocarcinoma (ICC) is a highly lethal primary liver tumour for which systemic therapies offer limited survival benefit.1–3 Over the past few decades, several signalling pathways associated with ICC development and progression have been identified. These molecular cascades affect the various characteristics of malignant cholangiocytes, including proliferation, survival, invasion, metastasis and metabolism.1–5 Thus, delineation of these pathways and their crosstalk may aid tailoring innovative therapies for this challenging disease.